

## SUITABILITY PETITION

### **Petitioner:**

Aurora Pharmaceutical, Inc.  
1196 Hwy 3 South  
Northfield, MN, 55057

### **Action Requested:**

The petitioner requests an FDA permission to submit an abbreviated new animal drug application (ANADA) for a generic meloxicam oral solution (1.5 mg/mL and 0.5 mg/mL strengths) for use in dogs that differs from reference listed new animal drug (RLNAD) in **dosage form**. The RLNAD is Metacam<sup>®</sup> (meloxicam) Oral Suspension (1.5 mg/mL and 0.5 mg/mL strengths), sponsored by Boehringer Ingelheim Animal Health USA, Inc. under NADA 141-213 for the control of pain and inflammation associated with osteoarthritis in dogs. The petition is submitted under the provisions of Section 512(n)(3) of the Federal Food Drug and Cosmetic Act.

### **Statement of Grounds:**

The proposed generic copy will utilize the same active as RLNAD. Recommended dosage is not changed. The justification for the proposed change of the dosage form is improved uniformity and convenience of a solution vs. suspension that requires shaking.

Metacam<sup>®</sup> (meloxicam) Oral Suspension is an oral suspension that requires shaking the liquid and is approved in two strengths, 1.5 mg and 0.5 mg meloxicam per mL of liquid. The approved dosage of meloxicam for oral administration in dogs is 0.09 mg/lb (0.2 mg/kg) of body weight only on the first day of treatment, and for all treatments after day 1, 0.045 mg/lb (0.1 mg/kg) of body weight.

The proposed generic dosage form is a meloxicam oral solution that does not require shaking, and is available in the same two strengths as the RLNAD product, 1.5 mg and 0.5 mg meloxicam per mL of liquid. The approved dosage of meloxicam for oral administration in dogs is 0.09 mg/lb (0.2 mg/kg) of body weight only on the first day of treatment, and for all treatments after day 1, 0.045 mg/lb (0.1 mg/kg) of body weight.

No patents are listed in the Green Book for the approved NADA 141-213.

Marketing exclusivity for Metacam<sup>®</sup> (meloxicam) Oral Suspension was expired 4/15/2008.

Side-by side comparison of Aurora's generic product Meloxicam Oral Solution with reference listed new animal drug Metacam<sup>®</sup> (meloxicam) Oral Suspension is presented hereinafter.

<b>Subject</b>	<b>RLNAD</b>	<b>Aurora's generic</b>
Proprietary name (strengths)	Metacam® Oral Suspension (meloxicam 1.5 mg/mL; meloxicam 0.5 mg/mL)	Meloxicam Oral Solution (meloxicam 1.5 mg/mL; meloxicam 0.5 mg/mL)
Established name	Meloxicam	Meloxicam
Sponsor	Boehringer Ingelheim Animal Health USA, Inc. 3239 Satellite Blvd., Duluth, GA 30096	Aurora Pharmaceutical, Inc. 1196 Hwy 3 South, Northfield, MN 55057
Pharmacological category	Non-steroidal anti-inflammatory drug	Non-steroidal anti-inflammatory drug
Dosage form	Suspension	Solution
Active ingredient	Each mL of suspension contains 1.5 mg or 0.5 mg of meloxicam after shaking	Each mL of solution contains 1.5 mg or 0.5 mg of meloxicam
How supplied	1) Metacam® 1.5 mg/mL Oral Suspension: 10, 32, 100 and 180 mL dropper bottles with measuring syringe. 2) Metacam® 0.5 mg/mL Oral Suspension: 15 and 30 mL dropper bottles with measuring syringe.	1) Meloxicam 1.5 mg/mL Oral Solution: 10, 32, 100 and 180 mL dropper bottles with measuring syringe. 2) Meloxicam 0.5 mg/mL Oral Solution: 15 and 30 mL dropper bottles with measuring syringe.
How dispensed	Rx	Rx
Route of administration	Oral	Oral
Species/Class	Dog	Dog
Recommended dosage	0.09 mg/lb (0.2 mg/kg) of body weight only on the first day of treatment, and for all treatments after day 1, 0.045 mg/lb (0.1 mg/kg) of body weight.	0.09 mg/lb (0.2 mg/kg) of body weight only on the first day of treatment, and for all treatments after day 1, 0.045 mg/lb (0.1 mg/kg) of body weight.
Indications	Metacam® Oral Solution is administered for the control of pain and inflammation associated with osteoarthritis in dogs.	Meloxicam Oral Solution is administered for the control of pain and inflammation associated with osteoarthritis in dogs.

**Environmental Impact:**

In accordance with 21 CFR 25.15, Aurora Pharmaceutical, Inc. claims that the agency requested action in this suitability petition qualifies for categorical exclusion from the requirement to prepare an environmental assessment as set forth in 21 CFR 25.30(h). We confirm that to our knowledge no extraordinary circumstances exist that may significantly affect the quality of the human environment as described in 21 CFR 25.21.

**Economic Impact:**


An economic impact analysis will be provided if requested after review of this petition.

**Labeling:**

General labeling information for the proposed generic Meloxicam Oral Solution will be essentially the same as the reference listed new animal drug Metacam<sup>®</sup> (meloxicam) Oral Suspension labeling (attachment #1 and #2), except the changes in dosage form from suspension to solution, no shaking instructions to suspend meloxicam, and information specific for the generic drug, namely proprietary name, how supplied and directions for use, “manufactured by” information, NDC#, label ID and revision date; NADA# will be replaced with ANADA#.

**Certification:**

The undersigned certifies, that, to the best knowledge and belief of the undersigned, this petition includes all information and views on which the petition relies, and that it includes representative data and information known to the petitioner that are unfavorable to the petition.

 11/02/2022  
11/02/2022 10:03:06 am

SigPlus1

---

Alina Garbar, PhD                      Date  
RA Director  
Aurora Pharmaceutical, Inc.

Attachment 1. Metacam<sup>®</sup> (meloxicam) 1.5 mg/mL Oral Suspension, labeling by Boehringer Ingelheim Vetmedica, Inc. rev 08/2019

Attachment 2. Metacam<sup>®</sup> (meloxicam) 0.5 mg/mL Oral Suspension, labeling by Boehringer Ingelheim Vetmedica, Inc. rev 08/2019